Skip to Main Content

Paper Details

Clinical activity of CC-90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignancies.
Cancer
9
2022
Author NameAffiliation
Giuseppe CuriglianoEuropean Institute of Oncology, IRCCS, University of Milan
Johann S de BonoThe Institute of Cancer Research and Royal Marsden Hospital
  • 1 - 2

Datasets

Release 1.2